Servier

Servier is a French multinational pharmaceutical company that develops, manufactures, and markets medicines worldwide. Founded in 1954 by Jacques Servier, it remains privately owned by the Servier family through the group Laboratoires Servier and is headquartered in Suresnes, outside Paris. It positions itself as an independent pharmaceutical company with a global footprint and a substantial focus on research and development.

The company operates across several therapeutic areas, including cardiovascular disease, oncology, neuroscience, immune and inflammatory diseases, and metabolic disorders. Its portfolio includes established medicines such as perindopril, an ACE inhibitor marketed as Coversyl and Prestarium, and ivabradine, used for certain heart conditions and sold under brand names Procoralan or Corlentor in different markets. Servier also engages in the development and marketing of generic and biosimilar products, as well as collaborations and licensing deals.

Servier is organized as a family-owned business and has pursued global expansion through internal growth and partnerships, maintaining a network of manufacturing sites, research centers, and regional subsidiaries. The company has historically invested in drug development and has been involved in partnerships with other pharmaceutical firms to expand its product portfolio.

In the Mediator affair, the company was at the center of a major public health controversy in France. The drug benfluorex, marketed as Mediator, was withdrawn in 2009 after safety concerns linked to valvular heart disease and deaths emerged. The affair led to investigations and civil lawsuits and highlighted debates over drug regulation, medical messaging, and pharmacovigilance. Servier has since faced ongoing scrutiny and legal action related to the case.